Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
:PEPG
PEPG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.16 - $19.30
Previous CloseN/A
Volume7.67K
Average Volume (3M)404.91K
Market Cap
$46.94M
Enterprise Value$158.75M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 20, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.98
Shares Outstanding32,595,737
10 Day Avg. Volume250,943
30 Day Avg. Volume404,912
Standard Deviation0.28
R-Squared0.07
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap3.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-134.08
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$14.00Price Target Upside872.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical Study ProgressCONNECT2 is intended to support a potential accelerated approval and has been cleared to start in the UK so far.
Patient ResponseThe two patients who were reported to have asymptomatic hypomagnesemia have returned to the normal baseline level with the help of oral magnesium supplementation suggesting the effect is reversible.
Bears Say
Regulatory ChallengesThe FDA issued a clinical hold for PepGen's Investigational New Drug application to initiate the phase 2 CONNECT2-EDO51 study in Duchenne muscular dystrophy patients.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.16 and its highest was $19.30 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $46.94M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 26 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Nov 07, 2024. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.868 by $0.208.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.81.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 32,595,737 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.868. Following the earnings report the stock price went down -21.697%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
---
PepGen Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (872.22% Upside)
$14.00 (872.22% Upside)
Blogger Sentiment
Bullish
PEPG Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.96%
12-Months-Change
Fundamentals
Return on Equity
-66.26%
Trailing 12-Months
Asset Growth
3.63%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.
---
PEPG Stock 12 Month Forecast
Average Price Target
$14.00
▲(872.22% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
PTC Therapeutics
―
Wave Life Sciences
―
Avidity Biosciences
―
Best Analysts Covering PEPG
1 Year
1 Year Success Rate
6/20 ratings generated profit
1 Year Average Return
-30.86%
reiterated a buy rating 21 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -30.86% per trade.
---